Related Experiment Videos
Tetrahydrobiopterin and maternal PKU
Richard Koch1, Kathryn Moseley, Flemming Guttler
1Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. rkoch8@earthlink.net
Molecular Genetics and Metabolism
|December 13, 2005
Summary
Phenylketonuria (PKU) in pregnancy can be managed with phenylalanine restriction and tetrahydrobiopterin (BH4). This approach led to a normal pregnancy outcome and suggests BH4 may reduce congenital heart defects in infants of mothers with PKU.
Area of Science:
- Biochemistry
- Genetics
- Maternal-Fetal Medicine
Background:
- Phenylketonuria (PKU) is a genetic disorder requiring strict phenylalanine restriction.
- Maternal PKU poses risks, including congenital heart defects (CHD) in offspring.
- Tetrahydrobiopterin (BH4) is a cofactor for phenylalanine hydroxylase (PAH).
Observation:
- A 29-year-old woman with PKU (PAH mutation R408W/F39L) was treated with phenylalanine restriction and oral BH4 during pregnancy.
- Excellent blood phenylalanine control was achieved with ease during gestation.
- The patient experienced no nausea or vomiting in the first trimester.
Findings:
- Successful pregnancy management in a patient with PKU using phenylalanine restriction and BH4.
- Achieved normal pregnancy outcome with effective phenylalanine level control.
- BH4 treatment was well-tolerated and facilitated phenylalanine management.
Implications:
- BH4 therapy may be a valuable adjunct in managing maternal PKU during pregnancy.
- Early or prophylactic BH4 treatment could potentially reduce the incidence of CHD in infants born to mothers with PKU.
- Further research is warranted to confirm the protective effect of BH4 against CHD in maternal PKU.